There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...
The standard dosing regimen was 700 mg of donanemab for the first three infusions, then 1,400 mg for each infusion after that ...
Eli Lilly and Company (NYSE: LLY) today announced positive results from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a ...
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...
Modified titration was associated with a 41% lower relative risk of ARIA-E than the standard dosing regimen. Topline results were announced from a phase 3b trial evaluating various dosing regimens of ...
showing a reduction in amyloid-related imaging abnormalities with edema/effusion at the 24-week primary endpoint for people receiving a slightly modified titration of donanemab in adults with ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...
An expert workgroup has developed the first appropriate use recommendations (AURs) for real-world use of the antiamyloid donanemab (Kisunla). “The role of appropriate use recommendations are to ...
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related ...
The“wonder” drug (or“miracle drug”) that some newspapers referred to is donanemab, an antibody that latches onto amyloid plaques in the brain and removes them. These plaques are the ...